论文信息 - Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations. - 字舞流文

Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.

Y. Drew | R. Plummer | M. Ranson | G. Rustin | M. Friedlander | C. Sessa | S. Kaye | C. Gourley | S. Nicum | K. Leunen | H. Swaisland | J. Mateo | M. Krebs | T. McGoldrick | W. Burke | I. Tchakov | L. R. Molife | K. Pemberton | S. Banerjee | P. McCormack